ICPT will launch new trial w/2,500 patients at 250 centers around the world. Estimated enrollment period (1.5yrs) plus time to interim analysis (1.5yrs) could push entry to market to year 2019-2020 if approved.
Meanwhile Gilead's NASH candidate is already in Phase 2 testing. Hugh expense plus extended time to
market equals a big down day for ICPT.